Co-administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO-C57
- PDF / 1,033,392 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 17 Downloads / 213 Views
Co‑administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO‑C57BL/6 Mice B. G. Mallikarjuna1 · Uma V. Manjappara1 Accepted: 17 January 2020 © Springer Nature B.V. 2020
Abstract It was observed previously that the gastro-peptide obestatin upregulated glycerolipid metabolism and PPARγ signalling in normal Swiss albino mice. In this study, the role of obestatin and the combined role of obestatin and rosiglitazone: a PPARγ agonist were assessed in diet-induced-obese C57BL/6 mice for their ability to reduce fat accumulation. Obesity was induced by feeding 60% calorie by fat high fat diet for 25 weeks. 160 nmol/KgBW obestatin, 3 mg/KgBW of rosiglitazone and their combination were administered intraperitoneally for eight days after induction of obesity. Decrease in food intake were observed in case of obestatin and obestatin + rosiglitazone for a period of 6 h after administration. Rosiglitazone showed increased gain in body weight. Whereas, obestatin and obestatin + rosiglitazone showed decrease in gain in body weight. Rosiglitazone showed significant decrease in plasma triglycerides and free fatty acids by 50.93%, and 24.98% respectively. The same decrease were retained upon co-administration with obestatin. Rosiglitazone showed increase in gluteal, cervical and subcutaneous fat and total fat content by 60%, 17.8%, 12% and 20% respectively. Combined administration of obestatin and rosiglitazone reduced all the rosiglitazone increased fat content of gluteal, cervical, subcutaneous and total fat to the control group levels. Histopathology studies show significantly decreased adipocyte size in epididymal adipose tissue from an average area of 250–4000 μm2 in the control to 250–1750 μm2 in the obestatin treated group and a further decrease to 250–1110 μm2 in the rosiglitazone treated group. Obestatin + rosiglitazone retained the reduction in average adipocyte area similar to that of rosiglitazone. An increase in average cell size in inguinal adipose tissue from 250–2250 to 250–3000 μm2 was observed for both obestatin and rosiglitazone but a drastic increase to 250–4000 μm2 was observed for obestatin + rosiglitazone. Doubling of liver triglyceride content by rosiglitazone was decreased by 13.5% upon co-administration with obestatin. These findings indicate co-administration of obestatin and rosiglitazone retain all the favourable parameters and reduce fat accumulation brought about by rosiglitazone. Keywords Obestatin · Rosiglitazone · Lipid metabolism · Epididymal fat · DIO mice
Introduction Metabolic syndrome is closely associated with overweight and obesity which is characterized by an imbalance of energy intake and expenditure leading to increased fat Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10989-020-10028-4) contains supplementary material, which is available to authorized users. * Uma V. Manjappara [email protected] 1
Department of Lipid Science, CSIR-Central Food Technological Research I
Data Loading...
